Organigram Global reported third-quarter revenue of CA$105.8 million, a 49% increase from the prior year, driven largely by its acquisition of German medical cannabis distributor Sanity Group.
The Moncton, New Brunswick-based licensed producer said international sales now account for 35% of total revenue, marking a significant shift in the company's geographic mix. The Sanity Group acquisition closed earlier this year, giving Organigram a foothold in Europe's growing medical cannabis market.
"This quarter demonstrates the strength of our diversified strategy," CEO Beena Goldenberg said in the earnings release. The results represent Organigram's highest quarterly revenue to date.
The European Play
Organigram acquired Sanity Group in a deal that valued the German distributor at approximately €20 million. Sanity operates medical cannabis pharmacies and e-commerce platforms across Germany, where patient enrollment has been climbing steadily since liberalization measures took effect in 2017.
Germany represents Europe's largest medical cannabis market by patient count, with roughly 300,000 registered patients as of late 2024. The country is also moving toward adult-use legalization through its controversial cannabis club model, though full retail sales remain years away.
The acquisition gives Organigram direct access to German patients and pharmacies, bypassing the need for third-party distributors. Industry analysts have noted that vertical integration in European markets offers better margins than export-only strategies, which dominated Canadian LPs' international efforts in prior years.
Domestic Performance
While international sales grew, Organigram's Canadian operations also posted gains. The company didn't break out domestic versus international revenue in its preliminary results, but the 35% international share implies Canadian sales still represent roughly CA$69 million of the quarterly total.
Canada's adult-use market has seen consolidation and price compression over the past two years, with many smaller producers exiting or being acquired. Organigram has maintained market share through its portfolio of brands including SHRED, Big Bag O' Buds, and Edison.
The company's focus on value-priced flower and pre-rolls has helped it compete as Canadian consumers gravitate toward lower price points. Average per-gram prices in Canada have fallen below CA$5 in many provinces, down from CA$10-plus in the first years of legalization.
What's Next
Organigram plans to release full quarterly financials in mid-January, which will provide more detail on margins, cash flow, and segment performance. Investors will be watching whether the Sanity Group integration maintains profitability or requires additional investment to scale.
The company has signaled interest in further European expansion, though it hasn't announced specific targets. Other potential markets include the United Kingdom, where medical cannabis prescriptions have grown rapidly, and France, which recently launched its own medical program.
Goldenberg said the company remains focused on "profitable growth in key markets," a shift from the revenue-at-any-cost approach that characterized many Canadian LPs in earlier years. With several competitors still posting losses, Organigram's ability to grow revenue while maintaining positive EBITDA could set it apart in a crowded field.
This article is based on original reporting by mjbizdaily.com.
